FILED:

FOR:

279431US0PCT

# CORREMEGRATO 14 OCT 2004

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Tatsuo KIMURA, et al.

SERIAL NO: New U.S. PCT Application Based on PCT/JP04/05355

GAU: EXAMINER: Herewith

PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES

OR SALTS THEREOF

# INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

#### REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- □ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

#### RELATED CASES

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- □ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

### CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR \$1.56(c) more than three months prior to the filing of this statement.

#### DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,

MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Corwin P. Umbach, Ph.D. Registration No. 40,211 Surinder Sachar

Registration No. 34,423

Customer Number

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

							æ	@ C G			
	Form PTO 1449			U.S. DEPARTMENT OF COMMERCE		ATTY DOCKET NO.	SERIAL NO 3120				
	Form PTO 1449 U.S. OEPARTMENT OF COMMER! (Modified) PATENT AND TRADEMARK OFFI					279431US0PCT	New U.S. PCT Application Based on PCT/JP04/05355				
	ľ	•				APPLICANT					
	LI	ST OF	REFE	RENCES CITED BY AP	PLICANT	Tatsuo KIMURA, et al.					
						FILING DATE	GROUP				
						Herewith					
	· ·					U.S. PATENT DOCUMENTS					
	EXAMINER INITIAL			DOCUMENT NUMBER			SUB CLASS	B FILING DATE SS IF APPROPRIATE			
-			AA								
- 1			AB								
			AC				<u> </u>				
			AD								
			AE								
			AF		ļ						
	-		AG		ļ						
			AH								
		_	AJ								
			AK				-				
			AL					_			
	-		AM								
			AN					-			
	FOREIGN PATENT DOCUMENTS										
	DOCUMENT DATE		COUNTRY	TRANSLATION YES NO							
			AO	03/035647	05/01/03	WO(English abstract only)				NO	
bst	act	onl	YAP	02/100833	12/19/02	WO(English abstract only)				NO	
bst	act	onl	yAQ	02/30420	04/18/02	WO(with English abstract)				· NO	
			AR	8-506807	07/23/96	JP(Equivalent of WO 94/13275)				NO	
			AS								
			AT								
- 1			ΑU								
			AV								
	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)										
	not		AW	Hyojun Ganka Gaku, 7 <sup>th</sup> edition, pages 103-107, Igaku-Shoin Ltd., 1998.							
	cons			Haniki ARE: "Atarach	i Canka Vol.	10 No. 7 pages 903-912-2002 ( with En	olieh abetr	act)			
- 1	Abst:		AX	Haruki, ABE: "Atarashii Ganka, Vol. 19, No. 7, pages 903-912, 2002 ( with English abstract).							
			AY	"Agouron buys drug discovery company" "Chiroscience steps up licensing talks", SCRIP No. 2229, page 13, May 6/9" 1997.							
			AZ	"Allergan's 1997 sales	fall*, SCRIP N	lo. 2307, page 10, February 6 <sup>th</sup> 1998.	Addi	tional Refe	rences	sheet(s) attached	
ĺ	Examir	Examiner /Gigi Huang/					Date Considered 10/21/2008				
						the transfer of			-74 - 17	w	
	*Exam	iner: In	itial if r	/Gigi Huang/ eference is considered, it considered. Include co	whether or not	t citation is in conformance with MPEP 60 with next communication to applicant.	Date Considered 10/21/2008 PEP 609; Draw line through citation if not in				

# JC20 Rec'd PCT/PTO 1 4 0CT 2009

New U.S. PCT Application Based on PCT/JP04/05355 Docket No.: 279431US0PCT

## STATEMENT OF RELEVANCY

1) References <u>AO-AO</u> have been cited in the International Search Report. Copies of these references are being submitted herewith only when not automatically provided by the International Searching Authority.
2) Reference have been cited in the corresponding Search Report. A copy of this reference is being submitted herewith.
3) References $\underline{AR}$ and $\underline{AW}$ - $\underline{AZ}$ are discussed in the specification. A copy of thes references is being submitted here with.
4) Referenceis additional prior art known to Applicant. A copy of these references is being submitted herewith.